Abstract | INTRODUCTION: METHODS: Eleven patients with lung cancer and 1 with ovarian cancer received erlotinib at a dose of 150 mg/d. The prevalence, severity, and time course of the adverse cutaneous reactions were assessed. RESULTS: CONCLUSIONS:
|
Authors | G Pitarch, J Garde, A Torrijos, A Juárez, M I Febrer, C Camps |
Journal | Actas dermo-sifiliograficas
(Actas Dermosifiliogr)
2008 Jan-Feb
Vol. 99
Issue 1
Pg. 54-60
ISSN: 0001-7310 [Print] Spain |
Vernacular Title | Efectos cutáneos adversos causados por erlotinib. |
PMID | 18206087
(Publication Type: Journal Article)
|
Chemical References |
- Quinazolines
- Erlotinib Hydrochloride
- ErbB Receptors
|
Topics |
- Adult
- Aged
- Drug Eruptions
(etiology, pathology)
- ErbB Receptors
(antagonists & inhibitors)
- Erlotinib Hydrochloride
- Female
- Humans
- Male
- Middle Aged
- Prospective Studies
- Quinazolines
(adverse effects)
|